{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-040611","form_type":"8-K","ticker":"SRZN","cik":"0001824893","company_name":"Surrozen, Inc./DE","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.504947+00:00","generated_at":"2026-06-11T23:12:58.613824+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Surrozen Q2 net loss $9.4M; cash runway extended into 2025 on prioritization","bullets":["Net loss of $9.4M improved from $13.9M YoY; cash and securities $53.4M (down from $61.7M in Q1).","R&D expenses fell to $6.9M from $9.6M YoY; G&A expenses to $3.3M from $4.5M YoY.","SZN-043 Phase 1a enrollment continues; safety data expected by end of 2023; Phase 1b in alcoholic hepatitis planned for 2024.","SZN-1326 Phase 1a enrollment continues; Phase 1b in ulcerative colitis planned for 2024, proof-of-concept data expected H2 2024.","Boehringer Ingelheim partnership may trigger $10M milestone in 2024 upon Fzd-4 candidate nomination."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-040611","json":"https://secwatch.observer/filing/0000950170-23-040611.json","markdown":"https://secwatch.observer/filing/0000950170-23-040611.md","text":"https://secwatch.observer/filing/0000950170-23-040611.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824893/000095017023040611/0000950170-23-040611-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824893/000095017023040611/srzn-20230809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T23:12:58.613824+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d1d7cbfea073ccc8f3514bea4fefaf39e4f613d8","claim":"Surrozen, Inc./DE reported second quarter ended June 30, 2023 results: net income Net loss for the second quarter ended June 30, 2023 was $9.4 million, as compared to $13.9 million for the same period i.","evidence_excerpt":"Net loss for the second quarter ended June 30, 2023 was $9.4 million, as compared to $13.9 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824893/000095017023040611/0000950170-23-040611-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss for the second quarter ended June 30, 2023 was $9.4 million, as compared to $13.9 million for the same period i"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}